Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Infections

Heart and Blood Diseases

Rare Diseases

Lymphoma

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Hematologic Neoplasms

Anemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Myeloproliferative Disorders

Lymphoma, B-Cell

Burkitt Lymphoma

Anemia, Refractory, with Excess of Blasts

Waldenstrom Macroglobulinemia

Anemia, Refractory

Blast Crisis

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hematologic Diseases

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Bone Marrow Diseases

Communicable Diseases

Epstein-Barr Virus Infections

Virus Diseases

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Neoplasms, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Cell Transformation, Neoplastic

Carcinogenesis

Neoplastic Processes

Syndrome

Preleukemia

Myelodysplastic Syndromes

Myeloid Leukemia

Acute Myeloid Leukemia

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Chronic Graft Versus Host Disease

Acute Non Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Mantle Cell Lymphoma

Follicular Lymphoma

B-cell Lymphoma

Marginal Zone Lymphoma

Acute Graft Versus Host Disease

Chronic Myeloproliferative Disorders

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Includes dose adjustment of T regulatory (Treg) and CD3+ T effector (CD3+ Teff) cells in recipients of double UCB transplantation

Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10\^6/kg, 10 x 10\^6/kg, 30 x 10\^6/kg, 100 x 10\^6/kg and 300 x 10\^6/kg)

Treg cells

Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10\^6 cells/kg, 6 x 10\^6 cells/kg, 9 x 10\^6 cells/kg, 12 x 10\^6 cells/kg, and 15 x 10\^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts

CD3+ Teff cells

Given intravenously on Days -8 through -6, 25 mg/m\^2 over 1 hour

Given intravenously on Day -7 and -6, 60 mg/kg

Given on Days -4 through -2, 165 cGY twice a day.

Total body irradiation

Umbilical cord blood transplantation

Claudio Brunstein, MD, PhD

This is a unique dose-escalation trial that will titrate doses of umbilical cord blood (UCB) Treg and CD3+ Teff cells with the goal of infusing as many CD3+ Teff cells as possible without conferring grade II-IV acute graft-versus-host disease (GVHD).

In this study, the investigators propose to add UCB Treg and UCB CD3+ Teff cells to the two TCD UCB donor units with the goal of transplanting as many CD3+ Teff cells as possible without reintroducing risk of acute GVHD. The investigators hypothesize that Treg will permit the reintroduction of CD3+ Teff cells that will provide a bridge while awaiting HSC T cell recovery long term. The co-infusion of Treg will prevent GVHD without the need for prolonged pharmacologic immunosuppression.

Based on prior studies, the first patient will start at lowest dose combination (3 x 10\^6/kg of Treg and 3 x 10\^6/kg of CD3+ Teff cells).

One patient will be entered at each level with a minimum of 35 days to observe the patient prior to moving to the next dose level. (1) If GVHD does not occur, a "successful step", then the CD3+ Teff cell dose will increase to the next higher level for the next patient; (2) If GVHD occurs, a "failed step", then Treg dose will increase to the next higher level for the next patient. It would take a minimum of 5 (if no GVHD) and maximum of 9 patients (if GVHD is observed at each level) to complete all Treg:CD3+ Teff cell combinations.

An additional 10 patients will be enrolled to verify that this reflects the optimal combination and evaluate its safety profile.

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies

Determine the optimal cell dose mixture of UCB T regulatory and CD3+ T effector cells without the development of grade II-IV acute GVHD

reaction that occurs with 48 hours of product infusion

Determine the incidence of neutrophil recovery (absolute neutrophil count ≥ 500/uL) at day 42

Determine incidence of double and single unit chimerism at various time points

Determine incidence of viral and fungal infections at 1 year

Estimate the probability of survival at 1 year

Determine the incidence of grade III-IV acute GVHD at day 100

Determine the incidence of treatment related mortality (TRM) at 6 months

Determine the incidence of platelet recovery (platelet count ≥ 50,000/uL) at 1 year

Determine the incidence of chronic GVHD at 1 year

Determine the incidence of relapse at 1 year

Masonic Cancer Center, University of Minnesota

Primary Myelofibrosis

Thrombocytosis

Bone Marrow Neoplasms

CK0804 will be administered intravenously (IV) 100 million Treg Cells every 28 days up to 6 infusions.

CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.

CK0804

Tara Sadeghi

Stacy Minor

Trisha Yassear, CCRC

Mehrdad Abedi, MD

Clinical Research Coordinator

Swati Goel, MD

Beatriz Raposo Corrandini, MSc

Mark Heaney, MD

Alleyne Genevieve

Lucia Masarova, MD

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

1. Safety Run-in

   The study will employ a 3+3+3 design to assess the safety and tolerability of the treatment based on treatment-limiting toxicities (TLTs) occurring up to 1 Cycle (28 days) after the first infusion.
2. Expansion

After a total of 9 participants completed 28 days and are evaluated for tolerability in the safety run-in phase, additional participants may be included in the expansion cohort in order to have approximately 24 evaluable myelofibrosis

This is a single-arm study consisting of a safety run-in (3+3+3 design) followed by an expansion cohort after completion of safety run-in data is evaluated for tolerability in the safety.

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib

* severe (grade 3 or 4) infusion-related toxicity within 24 hours (NCI-CTCAE V5.0) of exposure that does not resolve with standard of care treatment within 72 hours.
* regimen related death within 28 days

To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Cellenkos, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies	NCT01163201	Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Anemia, Refract... Chronic Myelopr... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Large Cell Non-... Lymphoblastic L... Burkitt's Lymph... High Grade Non-...	Treg cells CD3+ Teff cells Fludarabine Cyclophosphamid... Total body irra... Umbilical cord ...	18 Years - 55 Years	Masonic Cancer Center, University of Minnesota
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies	NCT01163201	Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Anemia, Refract... Chronic Myelopr... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Large Cell Non-... Lymphoblastic L... Burkitt's Lymph... High Grade Non-...	Treg cells CD3+ Teff cells Fludarabine Cyclophosphamid... Total body irra... Umbilical cord ...	18 Years - 55 Years	Masonic Cancer Center, University of Minnesota
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs	NCT05423691	Myelofibrosis	CK0804	18 Years -	Cellenkos, Inc.

Spots Global Cancer Trial Database for treg cells

Every month we try and update this database with for treg cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for treg cells

Every month we try and update this database with for treg cells cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for treg cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.